Newer anticoagulants may slow cognitive decline in Alzheimer's patients with atrial fibrillation
A study from Karolinska Institutet found that Alzheimer's patients with atrial fibrillation who took newer NOAC blood thinners experienced slower cognitive decline than those on warfarin or no anticoagulants. The effect was modest each year but could accumulate over time.
The study drew on Sweden's national dementia registry, SveDem, tracking 7,308 patients with both conditions. Researchers compared three matched groups: those on NOACs, those on warfarin, and those receiving no anticoagulants. Cognitive function was measured using the standardized Mini-Mental State Examination, a common screening tool in dementia care.
Beyond cognition, NOAC users showed lower risks of death, stroke, blood clots, and fractures compared to untreated patients. Warfarin also reduced stroke and clot risks but carried a higher risk of major bleeding. The researchers caution that the observational design cannot prove causation, since factors influencing treatment choice may also affect outcomes.
This finding could influence prescribing decisions for a growing population of older adults managing both heart rhythm problems and dementia. If the modest annual cognitive benefit accumulates over years, it may meaningfully extend quality of life for patients and reduce caregiver burden. Clinicians could weigh these potential cognitive advantages against bleeding risks when choosing anticoagulants. However, the observational nature means results should be confirmed through randomized trials before changing practice.